Predictive data models can be used to identify when patients may miss their appointments, reduce these incidents and increase scheduling efficiency. Here are some tips for the physician practice setting…
RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors
In a systematic literature review, researchers found that rheumatoid arthritis patients taking etanercept were less likely to discontinue their treatment than patients using any of five other tumor necrosis factor inhibitors…
Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020
NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…
Malignancy Risk Varies with Treatment in Systemic Necrotizing Vasculitis
NEW YORK (Reuters Health)—The risk of malignancy in patients with systemic necrotizing vasculitis varies according to the treatment received, according to an analysis of five randomized controlled trials. Previous studies reported an increased risk of malignancy in patients with systemic necrotizing vasculitis, and a more recent study from the European Vasculitis Study Group, based on…
One-Third of U.S. Healthcare Spending Is Administrative Costs
(Reuters Health)—U.S. insurers and providers spent more than $800 billion in 2017 on administration, or nearly $2,500 per person—more than four times the per-capita administrative costs in Canada’s single-payer system, a new study finds. Over one-third of all healthcare costs in the U.S. were due to insurance company overhead and provider time spent on billing,…
State Legislative Update: Setting the Stage for 2020 & Beyond
In the new year, ACR advocacy staff will be working to advance bills to reform step therapy, prior authorization and more in state legislatures across the country.
Off-Label Coverage of Mycophenolate for Scleroderma under Medicare Part D
Based on a request by the ACR Insurance Subcommittee, off-label use of mycophenolate for scleroderma has been added to a Medicare-approved compendium.
EULAR/ACR Criteria Identify SLE in Hospitalized Pericarditis Patients
NEW YORK (Reuters Health)—New European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria can be used to identify patients with systemic lupus erythematosus (SLE) in an unselected group of patients hospitalized for pericardial effusion, new findings show.1 “Overall, in patients with pericardial effusion and positive ANA, the diagnosis of SLE could be ruled out…
Tears of Knee Ligaments & Meniscus Carry Highest Arthritis Risk
(Reuters Health)—Young adults who have had knee injuries are much more likely than uninjured peers to develop knee osteoarthritis (OA) by middle age, especially if they have broken bones or torn connective tissue, a recent study suggests. Cruciate ligament injuries were associated with a 19.6% greater risk of knee osteoarthritis, the study found. Meniscal tears…
Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
In a phase 3 study, ixekizumab proved safe and effective for improving the signs and symptoms of non-radiographic axial spondyloarthritis (axSpA) in combination with conventional background medications, such as NSAIDs…
- « Previous Page
- 1
- …
- 223
- 224
- 225
- 226
- 227
- …
- 815
- Next Page »